Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

bioventus inc - BVS

BVS

Close Chg Chg %
12.27 0.02 0.16%

Pre-Market

12.29

+0.02 (0.16%)

Volume: 244.76K

Last Updated:

Nov 27, 2024, 4:00 PM EDT

Trade Now

Company Overview: bioventus inc - BVS

BVS Key Data

Open

$12.35

 Day Range

12.04 - 12.61

52 Week Range

3.81 - 14.37

 Market Cap

$802.06M

Shares Outstanding

65.37M

 Public Float

44.65M

Beta

0.88

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.62

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

500.26K

  

BVS Performance

1 Week
 
 4.78%
 
1 Month
 
 -7.12%
 
3 Months
 
 22.09%
 
1 Year
 
 194.24%
 
5 Years
 
 N/A
 

BVS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About bioventus inc - BVS

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

BVS At a Glance

Bioventus, Inc.
4721 Emperor Boulevard
Durham, North Carolina 27703
Phone 1-919-474-6700 Revenue 512.35M
Industry Medical Specialties Net Income -156,230,000.00
Sector Health Technology 2023 Sales Growth 0.045%
Fiscal Year-end 12 / 2024 Employees 970
View SEC Filings

BVS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.644
Price to Book Ratio 1.921
Price to Cash Flow Ratio 21.517
Enterprise Value to EBITDA 10.224
Enterprise Value to Sales 1.464
Total Debt to Enterprise Value 0.546

BVS Efficiency

Revenue/Employee 528,190.722
Income Per Employee -161,061.856
Receivables Turnover 4.164
Total Asset Turnover 0.469

BVS Liquidity

Current Ratio 1.527
Quick Ratio 1.007
Cash Ratio 0.211

BVS Profitability

Gross Margin 62.331
Operating Margin 3.125
Pretax Margin -23.639
Net Margin -30.493
Return on Assets -8.861
Return on Equity -39.471
Return on Total Capital -16.591
Return on Invested Capital -15.264

BVS Capital Structure

Total Debt to Total Equity 235.886
Total Debt to Total Capital 70.228
Total Debt to Total Assets 50.496
Long-Term Debt to Equity 217.506
Long-Term Debt to Total Capital 64.756
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bioventus Inc - BVS

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
321.16M 430.90M 512.12M 512.35M
Sales Growth
-5.58% +34.17% +18.85% +0.04%
Cost of Goods Sold (COGS) incl D&A
95.12M 140.41M 202.19M 192.99M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
28.64M 38.68M 72.81M 57.37M
Depreciation
1.08M 3.20M 5.77M 12.12M
Amortization of Intangibles
27.57M 35.48M 67.04M 45.24M
COGS Growth
-3.78% +47.61% +44.00% -4.55%
Gross Income
226.04M 290.49M 309.93M 319.35M
Gross Income Growth
-6.32% +28.51% +6.69% +3.04%
Gross Profit Margin
+70.38% +67.42% +60.52% +62.33%
2020 2021 2022 2023 5-year trend
SG&A Expense
193.00M 239.31M 327.17M 303.34M
Research & Development
11.17M 15.19M 25.94M 13.45M
Other SG&A
181.84M 224.12M 301.23M 289.89M
SGA Growth
-5.09% +23.99% +36.71% -7.28%
Other Operating Expense
- - - -
-
Unusual Expense
12.80M 33.62M 203.70M 94.16M
EBIT after Unusual Expense
20.24M 17.57M (220.94M) (78.15M)
Non Operating Income/Expense
3.18M (4.44M) (10.77M) (2.29M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - (1.00M)
-
Interest Expense
7.51M 5.50M 32.19M 40.68M
Interest Expense Growth
-65.21% -26.69% +484.87% +26.36%
Gross Interest Expense
7.51M 5.50M 32.19M 40.68M
Interest Capitalized
- - - -
-
Pretax Income
15.91M 7.62M (263.90M) (121.11M)
Pretax Income Growth
+64.25% -52.12% -3,563.24% +54.11%
Pretax Margin
+4.96% +1.77% -51.53% -23.64%
Income Tax
1.19M (1.97M) (50.51M) 85.00K
Income Tax - Current - Domestic
996.00K 7.42M 2.00M 1.35M
Income Tax - Current - Foreign
707.00K 367.00K 289.00K 1.11M
Income Tax - Deferred - Domestic
(511.00K) (9.55M) (49.94M) (4.83M)
Income Tax - Deferred - Foreign
- (210.00K) (2.85M) 2.46M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - (1.00M)
-
Other After Tax Income (Expense)
- - - (5.89M)
-
Consolidated Net Income
8.83M 9.59M (213.39M) (121.20M)
Minority Interest Expense
(1.69M) (9.79M) (54.69M) (24.46M)
Net Income
10.52M 19.38M (158.70M) (96.74M)
Net Income Growth
+47.88% +84.24% -919.12% +39.05%
Net Margin Growth
+3.27% +4.50% -30.99% -18.88%
Extraordinaries & Discontinued Operations
- - - (59.49M)
-
Discontinued Operations
- - - (59.49M)
-
Net Income After Extraordinaries
10.52M 19.38M (158.70M) (156.23M)
Preferred Dividends
- - - 6.13M
-
Net Income Available to Common
4.38M 19.38M (158.70M) (156.23M)
EPS (Basic)
0.0771 0.3254 -2.5852 -2.4938
EPS (Basic) Growth
+764.66% +322.05% -894.47% +3.54%
Basic Shares Outstanding
56.83M 59.55M 61.39M 62.65M
EPS (Diluted)
0.0771 0.3254 -2.5852 -2.4938
EPS (Diluted) Growth
+764.66% +322.05% -894.47% +3.54%
Diluted Shares Outstanding
56.83M 59.55M 61.39M 62.65M
EBITDA
61.69M 89.87M 55.57M 73.38M
EBITDA Growth
-9.63% +45.69% -38.17% +32.04%
EBITDA Margin
+19.21% +20.86% +10.85% +14.32%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 12.333
Number of Ratings 3 Current Quarters Estimate 0.083
FY Report Date 12 / 2024 Current Year's Estimate 0.405
Last Quarter’s Earnings 0.06 Median PE on CY Estimate N/A
Year Ago Earnings 0.02 Next Fiscal Year Estimate 0.656
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 2 3 3
Mean Estimate 0.08 0.07 0.41 0.66
High Estimates 0.09 0.10 0.41 0.78
Low Estimate 0.08 0.05 0.40 0.48
Coefficient of Variance 7.82 45.41 1.97 23.87

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Bioventus Inc - BVS

Date Name Shares Transaction Value
Jun 26, 2024 Anthony D'Adamio SVP & General Counsel 95,576 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.57 per share 532,358.32
Jun 26, 2024 Katrina J. Church SVP & Chief Compliance Officer 41,199 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.57 per share 229,478.43
Jun 26, 2024 Mark Singleton SVP & CFO 84,895 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.57 per share 472,865.15
Jun 25, 2024 Anthony D'Adamio SVP & General Counsel 19,850 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 25, 2024 Mark Singleton SVP & CFO 31,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 25, 2024 Katrina J. Church SVP & Chief Compliance Officer 8,600 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 19, 2024 Patrick Joseph Beyer Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 19, 2024 Patrick Joseph Beyer Director 49,943 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 19, 2024 Mary Kay Ladone Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 19, 2024 Mary Kay Ladone Director 52,488 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 19, 2024 Anthony D'Adamo SVP & General Counsel N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 19, 2024 Anthony D'Adamo SVP & General Counsel 92,938 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 19, 2024 Michelle McMurry-Heath Director 48,205 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 19, 2024 Michelle McMurry-Heath Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 14, 2024 John Anders Bartholdson Director 26,493 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 14, 2024 Guido J. Neels Director 26,493 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 14, 2024 Susan M. Stalnecker Director 26,493 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 14, 2024 Martin P. Sutter Director 26,493 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 14, 2024 William A. Hawkins Director 26,493 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 14, 2024 Alta Partners Management Co. LP Director 26,493 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Bioventus Inc in the News